acute myocardial infarction

Description Results NMA

Death 0.94 [0.88; 0.99]

captopril 6.25mg twice daily initialy titrated up to 50 mg twice daily (for 1 month) (n=29028)

vs.

placebo (n=29022)

double blind

Factorial plan

Sample size: 29028/29022

Primary endpoint: death

FU duration: 1 month

captopril6.25 mg initial dose, 12.5 mg 2 h later, and then 12.5 mg three times daily for 28 days (n=13634)

vs.

placebo (n=0)

double blind

Parallel groups

Sample size: 13634/0

Primary endpoint: death

FU duration: 1 month

captopril 6.25 mg, increasing to 50 mg t.d.s. (n=243)

vs.

placebo (n=250)

double blind

Parallel groups

Sample size: 243/250

Primary endpoint: regional wall motion

FU duration: 1 year

captopril 25 mg three times a day (n=149)

vs.

placebo (n=149)

double blind

Parallel groups

Sample size: 149/149

Primary endpoint: left ventricular volume index

FU duration: 1 year

captopril 25 mg three times daily or enalapril 5 mg three times daily (n=150)

vs.

placebo (n=75)

double blind

Parallel groups

Sample size: 150/75

Primary endpoint: LV function

FU duration: 1 year

captopril titrated dose in order to preserve their blood pressure (n=104)

vs.

placebo (n=104)

double blind

Parallel groups

Sample size: 104/104

Primary endpoint: exercise testing

FU duration: 1 month

captopril 50 mg twice daily (n=100)

vs.

placebo (n=0)

double blind

Parallel groups

Sample size: 100/0

Primary endpoint: Left ventricular volumes

FU duration: 3 months

captopril 25 mg three times a day (n=99)

vs.

placebo (n=0)

double blind

Parallel groups

Sample size: 99/0

Primary endpoint: none

FU duration: 1 year

intravenous followed by oral captopril (n=20)

vs.

placebo (n=18)

double blind

Parallel groups

Sample size: 20/18

Primary endpoint: none

FU duration: 3 months

slow intravenous bolus injection of 2.5 or 5.0 mg captopril followed by a continuous infusion of 1.5-2.0 mg/h for a period of 48 hours (n=22)

vs.

placebo (n=24)

double blind

Parallel groups

Sample size: 22/24

Primary endpoint: QRS complexes

FU duration: 48h

captopril, 6.25 mg, orally 15 min before thrombolysis (n=188)

vs.

placebo before thrombolysis (n=183)

double blind

Parallel groups

Sample size: 188/183

Primary endpoint: not defined

FU duration: 2h

captopril first dose 2-4 h after starting thrombolysis (the dose was then increased up to 25 mg every 8 h (n=31)

vs.

placebo (n=30)

double blind

Parallel groups

Sample size: 31/30

Primary endpoint: not defined

FU duration: 12h

captopril (n=21)

vs.

placebo (n=22)

double blind

Parallel groups

Sample size: 21/22

Primary endpoint: left ventricular volume indexes

FU duration: 14 days

12.5 mg of captopril three times daily (n=36)

vs.

placebo (n=36)

double blind

Parallel groups

Sample size: 36/36

Primary endpoint: none defined

FU duration: 28 days

enalapril (1 mg IV infusion +5-20 mg PO daily) for 6 months (n=3044)

vs.

placebo (n=3046)

double blind

Parallel groups

Sample size: 3044/3046

Primary endpoint: all cause death

FU duration: 6 months

intravenous enalaprilat (1 mg) then oral treatment for 1 month (n=22)

vs.

placebo (n=21)

double blind

Parallel groups

Sample size: 22/21

Primary endpoint: cardiac volumes and ejection fraction

FU duration: 1 year

fosinopril (n=142)

vs.

placebo (n=143)

double blind

Parallel groups

Sample size: 142/143

Primary endpoint: LV volumes

FU duration: 2 years

lisinopril (5 mg initial dose and then 10 mg daily) for 42 days (n=9435)

vs.

open control (n=9460)

open

Factorial plan

Sample size: 9435/9460

Primary endpoint: all cause mortality

FU duration: 6 months

2.5 mg ramipril orally prior to thrombolysis and 12 h later (n=51)

vs.

placebo (n=48)

double blind

Parallel groups

Sample size: 51/48

Primary endpoint: PAI-1 plasma levels

FU duration: 7 days

Long term death (1 year) 0.70 [0.54; 0.93]

death or severe congestive heart failure 0.67 [0.49; 0.93]

zofenopril initial dose 7.5 mg, up to a tagert dos eof 30mg twice daily (n=772)

vs.

placebo (n=784)

double blind

Parallel groups

Sample size: 772/784

Primary endpoint: death or severe congestive

FU duration: 1 year

Angioedema 0.28 [0.09; 0.86]

Cardiovascular death 1.15 [1.01; 1.31]

cancer death 1.00 [0.65; 1.52]

Hypotension 0.77 [0.53; 1.12]

Losartan, target dose of 50 mg daily (n=2744)

vs.

Captopril, traget dose of 50 mg 3 times daily (n=2733)

Double blind

Parallel groups

Sample size: 2744/2733

Primary endpoint: all-cause mortality

FU duration: 2.7 y

Cardiovascular death 1.00 [0.91; 1.09]

Cardiovascular death 1.00 [0.92; 1.09]

Valsartan, 160 mg twice daily (n=4909)

vs.

Captopril, 50 mg 3 times daily (n=4909)

Double blind

Parallel groups

Sample size: 4909/4909

Primary endpoint: mortality from any cause

FU duration: Median, 24.7 mo

Valsartan, 40 mg twice daily, plus captopril, 25 mg three times daily (n=4885)

vs.

Captopril, 25 mg 3 times daily (n=4909)

Double blind

Parallel groups

Sample size: 4885/4909

Primary endpoint: mortality from any cause

FU duration: Median, 24.7 mo

Total mortality 0.41 [0.17; 0.99]

Arrhythmic/sudden death 0.52 [0.18; 1.52]

Total mortality 0.82 [0.58; 1.15]

Arrhythmic/sudden death 0.71 [0.42; 1.19]

Total mortality 0.63 [0.38; 1.06]

Arrhythmic/sudden death 0.51 [0.25; 1.03]

Total mortality 0.48 [0.16; 1.43]

Arrhythmic/sudden death 0.63 [0.16; 2.48]

Total mortality 1.94 [0.84; 4.46]

Arrhythmic/sudden death 1.64 [0.36; 7.49]

amiodarone 1 g for 5 d; then 200 mg/d started within 4 weeks of AMI (n=98)

vs.

no amiodarone (usual care) (n=14)

open

Parallel groups

Sample size: 98/14

Primary endpoint: total mortality and arrhythmic events

FU duration: 12 mo

amiodarone 10 mg/kg per d for 3 weeks then 300-400 mg/d started 6-45 d after AMI (n=-9)

vs.

placebo (n=-9)

double blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 24 mo

amiodarone 800 mg/d for 1 week then 200-400 mg/d started 5-7 d after AMI (n=305)

vs.

placebo (n=308)

double blind

Parallel groups

Sample size: 305/308

Primary endpoint:

FU duration: 12 mo

amiodarone 600 mg/d for 1 week, 400 mg/d for 1 week then 200 mg/d started 10-30 d after AMI (n=115)

vs.

no amiodarone (n=123)

open

Parallel groups

Sample size: 115/123

Primary endpoint:

FU duration: 24 mo

amiodarone 200 mg 3 times daily for 1 wk; then 200 mg/d started < 8-10 d after AMI (n=59)

vs.

placebo (n=70)

double blind

Parallel groups

Sample size: 59/70

Primary endpoint:

FU duration: 6·42 mo

Ventricular tachycardia 0.41 [0.11; 1.49]

All cause death 0.96 [0.06; 14.87]

Profound hypotension 0.48 [0.04; 5.11]

Ventricular fibrillation 0.00 [0.00; NaN]

Cardiogenic shock 0.96 [0.06; 14.87]

Bradycardia ∞ [NaN; ∞]

Ventricular fibrillation 0.91 [0.84; 0.99]

Heart failure 1.07 [1.03; 1.11]

Profound hypotension 1.11 [1.07; 1.16]

II-III heart block 1.07 [1.03; 1.11]

Cardiogenic shock 1.11 [1.03; 1.20]

Bradycardia 7.42 [4.06; 13.56]

All cause death 1.06 [0.98; 1.14]

All cause death 1.00 [0.89; 1.13]

Heart failure 1.06 [0.95; 1.17]

II-III heart block 1.06 [0.95; 1.17]

severe arrhythmia 1.01 [0.81; 1.26]

Ventricular tachycardia 0.48 [0.29; 0.78]

All cause death 0.95 [0.20; 4.42]

Ventricular fibrillation 0.63 [0.11; 3.58]

Cardiogenic shock 0.00 [0.00; NaN]

Bradycardia 1.90 [0.18; 20.10]

Ventricular tachycardia 0.36 [0.18; 0.70]

All cause death 0.31 [0.03; 2.74]

Ventricular fibrillation 0.00 [0.00; NaN]

Cardiogenic shock ∞ [NaN; ∞]

severe arrhythmia 0.35 [0.17; 0.70]

Ventricular tachycardia 0.00 [0.00; NaN]

Ventricular fibrillation 0.00 [0.00; NaN]

Ventricular tachycardia ∞ [NaN; ∞]

All cause death 1.23 [0.50; 3.04]

Heart failure 1.38 [0.45; 4.25]

Ventricular fibrillation 0.66 [0.11; 3.88]

II-III heart block 1.38 [0.45; 4.25]

Ventricular tachycardia 0.27 [0.08; 0.92]

All cause death 0.20 [0.05; 0.87]

Heart failure 0.60 [0.36; 1.00]

II-III heart block 0.60 [0.36; 1.00]

Ventricular fibrillation 0.00 [0.00; NaN]

Cardiogenic shock 0.40 [0.08; 1.97]

Bradycardia ∞ [NaN; ∞]

Heart failure 2.52 [1.01; 6.30]

II-III heart block 2.52 [1.01; 6.30]

All cause death 0.45 [0.04; 4.76]

Profound hypotension ∞ [NaN; ∞]

Ventricular fibrillation 1.80 [0.17; 19.02]

All cause death 0.34 [0.04; 3.22]

Heart failure 0.66 [0.39; 1.10]

Ventricular fibrillation 1.79 [0.54; 5.90]

II-III heart block 0.66 [0.39; 1.10]

Cardiogenic shock 0.85 [0.39; 1.87]

Heart failure 0.98 [0.38; 2.55]

II-III heart block 0.98 [0.38; 2.55]

All cause death 0.36 [0.15; 0.88]

Bradycardia ∞ [NaN; ∞]

Ventricular tachycardia 0.93 [0.38; 2.28]

All cause death 0.38 [0.13; 1.08]

Heart failure 1.32 [0.08; 20.67]

II-III heart block 1.32 [0.08; 20.67]

Cardiogenic shock 0.00 [0.00; NaN]

severe arrhythmia 1.13 [0.57; 2.25]

Bradycardia 0.44 [0.09; 2.10]

Ventricular tachycardia 1.64 [0.83; 3.22]

All cause death 0.00 [0.00; NaN]

Heart failure 1.20 [0.38; 3.76]

II-III heart block 1.20 [0.38; 3.76]

Bradycardia ∞ [NaN; ∞]

All cause death 0.12 [0.02; 0.90]

Heart failure 0.84 [0.48; 1.46]

II-III heart block 1.06 [0.55; 2.06]

Cardiogenic shock 0.18 [0.02; 1.42]

severe arrhythmia 0.71 [0.43; 1.17]

All cause death 0.60 [0.12; 2.93]

II-III heart block 0.71 [0.31; 1.64]

Cardiogenic shock 0.30 [0.04; 2.46]

severe arrhythmia 0.68 [0.36; 1.30]

All cause death 0.24 [0.08; 0.69]

Cardiogenic shock 0.09 [0.01; 0.70]

II-III heart block 0.84 [0.48; 1.46]

severe arrhythmia 0.68 [0.45; 1.02]

severe arrhythmia 0.37 [0.20; 0.67]

All cause death 0.55 [0.21; 1.40]

Profound hypotension 1.67 [0.79; 3.54]

Cardiogenic shock 1.00 [0.26; 3.83]

All cause death 0.29 [0.06; 1.35]

severe arrhythmia 0.72 [0.24; 2.19]

All cause death 0.47 [0.14; 1.52]

All cause death ∞ [NaN; ∞]

II-III heart block 0.97 [0.06; 14.78]

severe arrhythmia 0.62 [0.28; 1.38]

All cause death 0.76 [0.59; 0.99]

Heart failure 0.75 [0.61; 0.93]

II-III heart block 0.75 [0.61; 0.93]

Bradycardia 1.34 [1.04; 1.73]

Profound hypotension 1.00 [0.70; 1.43]

Ventricular tachycardia 0.29 [0.11; 0.78]

All cause death 0.34 [0.12; 0.93]

Ventricular fibrillation 0.12 [0.01; 0.93]

severe arrhythmia 0.39 [0.23; 0.64]

Heart failure 0.86 [0.48; 1.55]

II-III heart block 0.86 [0.48; 1.55]

All cause death 0.66 [0.52; 0.85]

Ventricular fibrillation 0.52 [0.35; 0.80]

Cardiogenic shock 0.66 [0.42; 1.03]

2.4g of magnesium sulfate in 50 ml of 5% glucose solution intravenously over a 20 minutes period for 3 days (n=48)

vs.

50 ml of 5% glucose solution alone, imag (n=46)

double blind

Parallel groups

Sample size: 48/46

Primary endpoint:

FU duration:

24 h of intravenous magnesium sulphate (8 mmol initial bonus injection over about 15 minutes followed by 72 mmol in about 50 mLinfused over 24 h)4 (n=29011)

vs.

no magnesium infusion (n=29030)

open

Parallel groups

Sample size: 29011/29030

Primary endpoint:

FU duration:

2 g intravenous bolus of MgSO4 over 15 minutes, followed by a 17 g infusion of MgSO4 over 24 h (n=3113)

vs.

matched intravenous bolus and 24 h infusion of sterile waterndºã (n=3100)

double blind

Parallel groups

Sample size: 3113/3100

Primary endpoint:

FU duration:

8 mmol magnesium sulphate over 5 min followed by 65 mmol over 24-h infusion (n=40)

vs.

isotonic saline infusion (n=38)

double blind

Parallel groups

Sample size: 40/38

Primary endpoint:

FU duration:

8 g MgSO4 in 500 mL 15% glucose for 24 h intravenouslypj (n=25)

vs.

conventional treatmenton (n=23)

NA

Parallel groups

Sample size: 25/23

Primary endpoint:

FU duration:

MgSO4 2g/day for 3 daysn (n=32)

vs.

5% glucose (n=30)

open blind assessor

Parallel groups

Sample size: 32/30

Primary endpoint:

FU duration:

continuous infusion of 80 mmol magnesium chloride in 1000 mL dextrose˜K (n=150)

vs.

matching placebo (n=148)

double blind

Parallel groups

Sample size: 150/148

Primary endpoint:

FU duration:

magnesium 12g (50 mmol) in the first 24h, 3g (12 mmol) in the second 24h used within 2h after admission and within 30 minutes of thrombolytic therapy™ (n=50)

vs.

equal volume of isotonic glucose (n=50)

double blind

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration:

81 mval/daymagnesium sulphate infusion 13+/-9h after the onset of severe pain for 3 days (n=22)

vs.

80 mval/day NaCl infusion for 3 daysimag (n=20)

open

Parallel groups

Sample size: 22/20

Primary endpoint:

FU duration:

36 h intravenous infusion of magnesium sulphate (0.75 mEq/kg/body weight/12 h). (n=-9)

vs.

saline solution infusion (n=-9)

double blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

bolus injection of 8 mmol of magnesium followed by an infusion of 24 mmol over 24 h (n=89)

vs.

equivalent amount of normal saline, imag (n=91)

double blind

Parallel groups

Sample size: 89/91

Primary endpoint:

FU duration:

8mmol MgSO4 in 10 min, 62 mmol in 24hmag (n=31)

vs.

NaCl ¯B (n=26)

double blind

Parallel groups

Sample size: 31/26

Primary endpoint:

FU duration:

18 g (75.6 mmol) of Mg sulphate over 24 h started immediately after completion of thrombolytic therapy (n=181)

vs.

equivalent amount of salinexbitm (n=169)

double blind

Parallel groups

Sample size: 181/169

Primary endpoint:

FU duration:

50 mmol MgCl2 during the first 24 h, 12 mmol during the second 24 h (n=56)

vs.

isotonic glucose (n=74)

double blind

Parallel groups

Sample size: 56/74

Primary endpoint:

FU duration:

MgSO4 7 g (28 mmol) with 5 hon (n=75)

vs.

matching saline solution (n=75)

double blind

Parallel groups

Sample size: 75/75

Primary endpoint:

FU duration:

magnesium 22 g (91.6 mmol) within 48 h (67 mmol within first 24 h). (n=50)

vs.

isotonic glucose. (n=53)

double blind

Parallel groups

Sample size: 50/53

Primary endpoint:

FU duration:

22 g (91.6 mmol) within 48 h (67 mmol within first 24 h). (n=21)

vs.

isotonic glucose. (n=25)

double blind

Parallel groups

Sample size: 21/25

Primary endpoint:

FU duration:

magnesium 22 g (91.6mmol) within 48 h (67mmol within first 24 h)pj (n=96)

vs.

isotonic glucose (n=98)

double blind

Parallel groups

Sample size: 96/98

Primary endpoint:

FU duration:

5 g (8.12 mmol) of MgSO4 daily for 4 daysptomsce (n=-9)

vs.

2% dextrose solution for 3 daysm (n=-9)

double blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration:

65 mmol MgSO4 given over 24 h (n=92)

vs.

Saline (n=93)

double blind

Parallel groups

Sample size: 92/93

Primary endpoint:

FU duration:

magensium 50 mmol within 24 h (n=130)

vs.

isotonic NaCl. (n=122)

double blind

Parallel groups

Sample size: 130/122

Primary endpoint:

FU duration:

17 g MgSO4 with first 24 h.xbitm (n=31)

vs.

saline. (n=30)

double blind

Parallel groups

Sample size: 31/30

Primary endpoint:

FU duration:

magnesium 8 mmol over 5 min, 65 mmol over 24h imag (n=1159)

vs.

physiological saline hon (n=1157)

double blind

Parallel groups

Sample size: 1159/1157

Primary endpoint:

FU duration:

2.5 g MgSO4 once or twice a day for 7-14 dayssce (n=125)

vs.

usual care (n=102)

double blind

Parallel groups

Sample size: 125/102

Primary endpoint:

FU duration:

100 mL (4 g) potassium-magnesium aspartate IV. for the first day, 50 ml for rest 4 datio (n=1691)

vs.

routine AMI treatmentƒkB (n=1488)

open

Parallel groups

Sample size: 1691/1488

Primary endpoint:

FU duration:

Thrombotic Stroke 0.60 [0.40; 0.89]

myocardial infarction 0.47 [0.38; 0.58]

Major Bleeding 3.85 [2.34; 6.35]

Death 0.90 [0.74; 1.10]

Minor Bleeding 3.03 [1.77; 5.20]

Death 0.58 [0.26; 1.31]

Revascularization 0.80 [0.51; 1.23]

Major Bleeding 2.26 [0.59; 8.67]

Thrombotic Stroke 0.00 [0.00; NaN]

myocardial infarction 0.69 [0.31; 1.53]

nicoumalone or phenprocoumon, target INR 2.8–4.8 (n=1700)

vs.

placebo (n=1704)

double blind

Parallel groups

Sample size: 1700/1704

Primary endpoint:

FU duration: 37 months (range 6-76)

coumadin(INR mean 2.4) +aspirin (n=298)

vs.

aspirin (n=289)

open

Parallel groups

Sample size: 298/289

Primary endpoint: death, MI or stroke

FU duration: 1 year

Death 0.28 [0.09; 0.82]

Revascularization 0.90 [0.58; 1.39]

Major Bleeding 1.03 [0.21; 5.09]

Minor Bleeding 1.68 [0.92; 3.07]

intrcranial major bleeding NaN [NaN; NaN]

myocardial infarction 0.96 [0.46; 2.01]

all cause death, MI, thrombo-embolic stroke 0.57 [0.32; 1.00]

coumadin (phenprocoumon or acenocoumarol) target INR 3-4 (n=325)

vs.

aspirin 80mg daily (n=336)

open

Parallel groups

Sample size: 325/336

Primary endpoint: death, MI or stroke

FU duration: 1 year (range 0-26 months)

Revascularization 0.33 [0.19; 0.57]

myocardial infarction 0.28 [0.08; 0.98]

Death ∞ [NaN; ∞]

Major Bleeding 1.03 [0.15; 7.21]

Minor Bleeding 2.57 [0.51; 13.04]

myocardial infarction 0.17 [0.03; 1.00]

Death 0.00 [0.00; NaN]

Revascularization 1.11 [0.45; 2.77]

Major Bleeding ∞ [NaN; ∞]

Minor Bleeding ∞ [NaN; ∞]

Thrombotic Stroke NaN [NaN; NaN]

Minor Bleeding 6.50 [1.52; 27.75]

Death 0.33 [0.07; 1.60]

Major Bleeding 2.50 [0.50; 12.46]

Thrombotic Stroke NaN [NaN; NaN]

myocardial infarction 0.67 [0.20; 2.26]

Major Bleeding 1.75 [1.24; 2.47]

Minor Bleeding 4.56 [3.58; 5.80]

Death 1.02 [0.90; 1.15]

Thrombotic Stroke 0.89 [0.66; 1.20]

intrcranial major bleeding 0.94 [0.45; 1.94]

myocardial infarction 1.02 [0.88; 1.17]

cardiovascular event 0.60 [0.52; 0.70]

non fatal MI 0.57 [0.48; 0.69]

cardiovascular death 0.69 [0.52; 0.92]

Death 0.73 [0.56; 0.94]

Major Bleeding 1.09 [0.70; 1.70]

Thrombotic Stroke 0.93 [0.53; 1.61]

Thrombotic Stroke 0.68 [0.48; 0.94]

stroke 0.67 [0.50; 0.88]

Major Bleeding 2.23 [1.24; 3.99]

Minor Bleeding 2.21 [1.55; 3.14]

cardiovascular event 0.97 [0.87; 1.09]

cardiovascular death 0.91 [0.77; 1.07]

Death 0.95 [0.83; 1.10]

intrcranial major bleeding 1.98 [0.68; 5.78]

myocardial infarction 1.04 [0.90; 1.22]

cardiovascular event 1.29 [1.10; 1.51]

non fatal MI 1.31 [1.09; 1.58]

Thrombotic Stroke 2.23 [1.27; 3.92]

cardiovascular death 1.07 [0.77; 1.49]

Death 1.03 [0.76; 1.41]

Major Bleeding 1.45 [0.86; 2.44]

cardiovascular event 0.71 [0.59; 0.86]

non fatal MI 0.56 [0.42; 0.75]

Thrombotic Stroke 0.50 [0.28; 0.91]

myocardial infarction 0.56 [0.42; 0.75]

all cause death, MI, thrombo-embolic stroke 0.71 [0.59; 0.86]

Major Bleeding 3.32 [1.51; 7.27]

Minor Bleeding 3.23 [2.27; 4.61]

Death 0.98 [0.74; 1.30]

Revascularization 0.90 [0.79; 1.02]

intrcranial major bleeding 2.84 [0.30; 27.32]

moderate-intensity coumarin target INR 2-3 (+aspirin) (n=135)

vs.

aspirin (n=139)

open

Parallel groups

Sample size: 135/139

Primary endpoint: reocclusion of the infarct-related artery

FU duration: 3 months

warfarin target INR 2–2.5 +aspirin (n=6)

vs.

placebo +aspirin (n=5)

double blind

Parallel groups

Sample size: 6/5

Primary endpoint: quantitative angiography

FU duration: 2.5 months

Warfarin target INR 2–3 +aspirin (n=70)

vs.

aspirin 100 mg/day (n=70)

open

Parallel groups

Sample size: 70/70

Primary endpoint:

FU duration: 1 year

warfarin 2.8–4.8 (n=1208)

vs.

placebo (n=1206)

double blind

Parallel groups

Sample size: 1208/1206

Primary endpoint:

FU duration: 37 months

warfarin target INR 1.5-2.5 + aspirin 81 mg daily (n=2522)

vs.

aspirin 162 mg/d (n=2537)

open

Parallel groups

Sample size: 2522/2537

Primary endpoint: all cause mortality

FU duration: 2.7 years

warfarin fixed dose 3mg/d + 80 mg ASA (n=5410)

vs.

aspirin 160 mg/d (n=3393)

double blind

Parallel groups

Sample size: 5410/3393

Primary endpoint: reinfarction, non-fatal ischaemic stroke, or cardiovascular death

FU duration: 14 months

warfarin fixed dose 1.25mg/d + ASA 75mg/d (n=1659)

vs.

aspirin alone (n=1641)

open

Parallel groups

Sample size: 1659/1641

Primary endpoint: Cardiovascular event and CV death

FU duration: 5 years

warfarin 1mg/d + aspirin 80mg/d (n=2028)

vs.

aspirin 160 mg/d (n=3393)

double blind

Parallel groups

Sample size: 2028/3393

Primary endpoint: reinfarction, non-fatal ischaemic stroke, or cardiovascular death

FU duration: 14 months

warfarin target INR 2-2.5 +ASA 75mg/d (n=4927)

vs.

ASA 160mg/d (n=4669)

open

Parallel groups

Sample size: 4927/4669

Primary endpoint: death, MI, ischaemic stroke

FU duration: 4 years

cardiovascular event 0.84 [0.71; 0.99]

non fatal MI 0.76 [0.59; 0.99]

Thrombotic Stroke 0.53 [0.29; 0.94]

all cause death, MI, thrombo-embolic stroke 0.81 [0.69; 0.95]

Major Bleeding 4.09 [1.90; 8.82]

Minor Bleeding 2.62 [1.83; 3.75]

Death 1.03 [0.79; 1.36]

intrcranial major bleeding 4.96 [0.58; 42.38]

warfarin target INR 2.8-4.2 (n=1216)

vs.

ASA 160mg/d (n=1206)

NA

Parallel groups

Sample size: 1216/1206

Primary endpoint: death, MI, ischaemic stroke

FU duration: 48 months

vascular death 0.75 [0.35; 1.62]

non fatla stroke ∞ [NaN; ∞]

non fatal MI 0.33 [0.07; 1.57]

vascular events 0.67 [0.36; 1.23]

non vascular death NaN [NaN; NaN]

vascular death 0.70 [0.43; 1.14]

major bleeding 0.98 [0.06; 15.56]

non fatla stroke 0.49 [0.04; 5.36]

non fatal MI 0.76 [0.29; 2.02]

vascular events 0.70 [0.46; 1.07]

non vascular death NaN [NaN; NaN]

vascular death 0.80 [0.73; 0.87]

non fatla stroke 0.56 [0.35; 0.88]

non fatal MI 0.46 [0.35; 0.61]

vascular events 0.74 [0.68; 0.80]

major bleeding 1.34 [0.73; 2.46]

non vascular death 0.29 [0.06; 1.38]

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death 0.00 [0.00; NaN]

vascular death 1.12 [0.07; 16.98]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 1.12 [0.07; 16.98]

non vascular death NaN [NaN; NaN]

non fatal MI 0.27 [0.08; 0.94]

vascular events 0.30 [0.10; 0.89]

vascular death 0.44 [0.04; 4.82]

non fatla stroke NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

aspirin (100 mg/day) for 3 months (n=50)

vs.

placebo (n=50)

double blind

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 3m

aspirin (325 mg on alternate days for 28 days) (n=313)

vs.

placebo (n=306)

double blind

Parallel groups

Sample size: 313/306

Primary endpoint:

FU duration: 1m

160 mg/day enteric-coated aspirin for one month (n=8587)

vs.

placebo (n=8600)

double blind

Parallel groups

Sample size: 8587/8600

Primary endpoint:

FU duration: 35d

aspirin 500mg/d starting 12 h after admissionand and then intermittently every third day for one month (n=10)

vs.

no aspirin (n=10)

open

Parallel groups

Sample size: 10/10

Primary endpoint:

FU duration: 30d (12m)

A1320 + D300, A1320 (n=25)

vs.

(n=28)

Parallel groups

Sample size: 25/28

Primary endpoint:

FU duration: 14d

325 mg aspirin daily with discontinuation of heparin (n=107)

vs.

placebo (n=95)

double blind

Parallel groups

Sample size: 107/95

Primary endpoint: patency of the infarct related artery

FU duration: 3m

non fatal MI 0.82 [0.70; 0.96]

vascular events 0.92 [0.87; 0.97]

non fatla stroke 0.89 [0.70; 1.13]

clopidogrel 75 mg daily (n=22961)

vs.

placebo (n=22891)

double-blind

Parallel groups

Sample size: 22961/22891

Primary endpoint: death, reinfarction, or stroke

FU duration: until discharge or up to 4 wee

clopidogrel (300-mg loading dose, followed by 75 mg once daily) (n=-9)

vs.

placebo (n=-9)

double blind

Sample size: -9/-9

Primary endpoint: death, reMI, occlusion

FU duration: 30 days

Dalteparin 150 mg/kg BID for 7–11 d (n=388)

vs.

placebo (n=388)

Double-blind

Parallel groups

Sample size: 388/388

Primary endpoint: Echocardiographic LV thrombus, arterial embolism

FU duration: in hospital

Dalteparin 100 mg/kg, 2 doses (n=54)

vs.

placebo (n=47)

Double-blind

Parallel groups

Sample size: 54/47

Primary endpoint: Angiographic TIMI flow in infarct-related vessel

FU duration: 14–21 d

reinfarction at 30 days 0.96 [0.47; 1.97]

death at 30 dayas 0.79 [0.33; 1.86]

Dalteparin first dose 90 IU/kg, then 120 IU/kg BID, 4–7 d (n=221)

vs.

UFH 4000–5000 IU bolus, then 800–1000 IU/h for 48 h (n=213)

open

Parallel groups

Sample size: 221/213

Primary endpoint: Angiographic 60-min TIMI flow

FU duration: 30 d

major bleeding NaN [NaN; NaN]

non fatla stroke ∞ [NaN; ∞]

non fatal MI NaN [NaN; NaN]

elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus (n=34)

vs.

placebo (n=36)

5 arms: 4 doses of elinogrel or placebo before the start of the diagnostic angiogram preceding primary PCI

double blind

Parallel groups

Sample size: 34/36

Primary endpoint: TIMI and ST resolution

FU duration: 30-37 days

phase IIb (dose-escalation study)

Enoxaparin 30 mg IV bolus, 1 mg/kg for 3–8 d (n=253)

vs.

placebo (n=243)

Double-blind

Parallel groups

Sample size: 253/243

Primary endpoint: Angiographic TIMI flow in infarct-related vessel

FU duration: 30 d

reinfarction at 30 days 0.64 [0.46; 0.88]

death at 30 dayas 0.89 [0.69; 1.15]

reinfarction at 30 days 1.00 [0.38; 2.61]

death at 30 dayas 0.90 [0.37; 2.17]

reinfarction at 30 days 0.74 [0.45; 1.23]

death at 30 dayas 0.57 [0.26; 1.25]

reinfarction at 30 days 0.15 [0.04; 0.54]

death at 30 dayas 0.68 [0.16; 2.98]

death at 30 dayas 1.25 [0.87; 1.80]

Enoxaparin 1 mg/kg BID, <=7d (n=2040)

vs.

UFH 60 U/kg bolus, then 12 IU/kg per h for 48 h (n=2038)

open

Parallel groups

Sample size: 2040/2038

Primary endpoint: In-hospital MI or RI

FU duration: 30 d

Enoxaparin 1 mg/kg BID, <=3d (n=200)

vs.

UFH 4000–5000 IU bolus, then 15 IU/kg per hour for >=3d (n=200)

open

Parallel groups

Sample size: 200/200

Primary endpoint: infarct-related artery patency

FU duration: 5–7 d

Enoxaparin 40 mg TID, 4 d (n=149)

vs.

UFH 5000 IU bolus, then 30 000 IU over 24 h for 4d (n=151)

90-min TIMI flow

Parallel groups

Sample size: 149/151

Primary endpoint: death, non-fatal reinfarction, or readmission with unstable angina

FU duration: 90 d

Enoxaparin 1 mg/kg BID, <=8d (n=160)

vs.

UFH 60 IU/kg, then 12 IU/kg per h for >=3d (n=82)

open

Parallel groups

Sample size: 160/82

Primary endpoint: MI, death, readmit for UA

FU duration: 30 d

Enoxaparin 1 mg/kg BID, <=7d (n=818)

vs.

UFH 60 IU/kg, then 12 IU/kg per h for >=3d (n=821)

open

Parallel groups

Sample size: 818/821

Primary endpoint: Angiographic TIMI flow

FU duration: 30 d

death in hospital 0.87 [0.76; 0.99]

death or reinfarction 0.87 [0.78; 0.96]

reinfarction during hospitalization 0.68 [0.52; 0.88]

death at 30 dayas 0.87 [0.78; 0.98]

Major bleeding 0.83 [0.64; 1.06]

reinfarction at 30 days 0.81 [0.65; 1.01]

fondaparinux 2.5 mg once daily up to 8 days (n=6036)

vs.

control (UFH or placebo) (n=6056)

from day 3 through day 9, all patients received either fondaparinux or placebo

double-blind

Factorial plan

Sample size: 6036/6056

Primary endpoint: death or reinfarction

FU duration: 30 days

Reviparin 3436–6871 IU BID for 7 d (weight adjusted) (n=7780)

vs.

placebo (n=7790)

Double-blind

Parallel groups

Sample size: 7780/7790

Primary endpoint: Death, MI, or stroke; death, MI, stroke, or recurrent ischemia

FU duration: 30 d

vascular death 0.50 [0.10; 2.61]

major bleeding NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events 0.50 [0.10; 2.61]

non vascular death NaN [NaN; NaN]

vascular death 5.00 [0.61; 41.25]

vascular events 5.00 [0.61; 41.25]

non vascular death NaN [NaN; NaN]

vascular death ∞ [NaN; ∞]

vascular events ∞ [NaN; ∞]

non vascular death NaN [NaN; NaN]

S (W) (n=50)

vs.

(n=50)

Parallel groups

Sample size: 50/50

Primary endpoint:

FU duration: 21d

Sulphinpyrazone 200 mg four times daily (n=49)

vs.

placebo (n=49)

Parallel groups

Sample size: 49/49

Primary endpoint:

FU duration: 10d

sulphinpyrazone, 4 x 200 mg daily for 7 days (n=15)

vs.

placebo (n=14)

double blind

Parallel groups

Sample size: 15/14

Primary endpoint: renal function

FU duration: 7d

vascular death NaN [NaN; NaN]

non fatla stroke NaN [NaN; NaN]

non fatal MI NaN [NaN; NaN]

vascular events NaN [NaN; NaN]

non vascular death NaN [NaN; NaN]

ticlopidine 500mg/d (n=24)

vs.

placebo (n=19)

double blind

Parallel groups

Sample size: 24/19

Primary endpoint:

FU duration: 3m

death in hospital 1.30 [0.47; 3.60]

reinfarction during hospitalization 0.19 [0.02; 1.64]

death in hospital 0.81 [0.34; 1.92]

reinfarction during hospitalization 0.99 [0.42; 2.34]

death in hospital 0.33 [0.04; 3.12]

reinfarction during hospitalization 2.00 [0.19; 21.51]

death in hospital 1.43 [0.61; 3.38]

reinfarction during hospitalization 2.14 [0.68; 6.78]

UFH nNo bolus, 1000 IU/h for 48 h (n=106)

vs.

No heparin (n=103)

open

Parallel groups

Sample size: 106/103

Primary endpoint: New MI, death

FU duration: In-hospital, 1 y (deat

UFH 5000 IU bolus, UFH 1000 IU/h for 48–120 h (n=324)

vs.

Placebo (n=320)

Double-blind

Parallel groups

Sample size: 324/320

Primary endpoint: Angiographic patency

FU duration: In-hospital

UFH 10 000 IU bolus, 1000 IU/h for 24 h (n=64)

vs.

Placebo (n=64)

Double-blind

Parallel groups

Sample size: 64/64

Primary endpoint: Reperfusion, angiographic patency, LVEF

FU duration: In-hospital

UFH no bolus, 15 IU/kg per h for 4 d; target aPTT 50–90 s (n=128)

vs.

No heparin (n=122)

open

Parallel groups

Sample size: 128/122

Primary endpoint: Death, recurrent MI, recurrent ischemia, angiographic patency

FU duration: 14 d

all cause death NaN [NaN; NaN]

all cause death 0.52 [0.30; 0.91]

cardiovascular death 0.41 [0.22; 0.79]

fatal and nonfatal MI 0.85 [0.36; 2.02]

Sudden death 0.69 [0.25; 1.92]

Acebutolol (initial dose intravenously) (n=14)

vs.

control (n=12)

open

Parallel groups

Sample size: 14/12

Primary endpoint:

FU duration: 1 month

Acebutolol 200mg twice daily (n=298)

vs.

placebo (n=309)

Double blind

Parallel groups

Sample size: 298/309

Primary endpoint: death

FU duration: 318 days

all cause death 0.97 [0.72; 1.31]

all cause death 0.51 [0.21; 1.21]

reinfarction 0.90 [0.49; 1.68]

Alprenolol 5-10 mg intravenously, followed by 200 mg twice a day (n=238)

vs.

placebo (n=242)

the 2 stratum <65 et >65 years are grouped together

Double blind

Parallel groups

Sample size: 238/242

Primary endpoint: NA

FU duration: About 1 year

Alprenolol 200mg twice daily (n=114)

vs.

placebo (n=116)

Double blind

Parallel groups

Sample size: 114/116

Primary endpoint: NA (sudden cardiac death may be)

FU duration: 2 years

all cause death 0.95 [0.88; 1.03]

all cause death 0.24 [0.03; 2.06]

all cause death 0.78 [0.52; 1.17]

Atenolol (initial dose intravenously) (n=8037)

vs.

control (n=7990)

No

Sample size: 8037/7990

Primary endpoint:

FU duration: 1 year

Atenolol (n=100)

vs.

(n=94)

Double

Sample size: 100/94

Primary endpoint:

FU duration: 1014 days

Atenolol (initial dose intravenously) (n=244)

vs.

(n=233)

No

Sample size: 244/233

Primary endpoint:

FU duration: 1-4y

all cause death NaN [NaN; NaN]

Betaxolol (n=16)

vs.

(n=15)

Double

Sample size: 16/15

Primary endpoint:

FU duration: 14 days

cardiac event (fatal and non fatal ) 0.55 [0.34; 0.89]

cardiovascular death 0.63 [0.11; 3.67]

fatal and nonfatal MI 0.52 [0.20; 1.32]

cardiac death 0.64 [0.11; 3.73]

reinfarction 0.47 [0.15; 1.50]

Carvedilol target dose 25 mg BID (n=77)

vs.

placebo (n=74)

Patients were subsequently withdrawn if the cardiac enzymes failed to show the typical pattern of acute myocardial necrosis¬

Double blind

Parallel groups

Sample size: 77/74

Primary endpoint: cardiovascular event

FU duration: 6 months

all cause death 1.71 [0.71; 4.14]

Labetalol (initial dose intravenously) (n=83)

vs.

control (n=83)

No

Sample size: 83/83

Primary endpoint:

FU duration: 1 year

all cause death 0.87 [0.69; 1.11]

all cause death 1.04 [0.07; 15.74]

all cause death NaN [NaN; NaN]

all cause death 1.00 [0.51; 1.94]

all cause death 0.64 [0.44; 0.95]

reinfarction 0.65 [0.43; 0.98]

all cause death 0.93 [0.70; 1.23]

cardiovascular death 0.93 [0.69; 1.26]

Sudden death 0.85 [0.48; 1.49]

cardiac death 0.98 [0.72; 1.32]

all cause death 0.58 [0.26; 1.28]

reinfarction 0.55 [0.32; 0.95]

all cause death 0.77 [0.48; 1.24]

Sudden death 0.41 [0.18; 0.93]

all cause death 0.79 [0.55; 1.13]

cardiac death 0.84 [0.57; 1.25]

Metoprolol (initial dose intravenously) (n=2877)

vs.

(n=2901)

Double

Sample size: 2877/2901

Primary endpoint:

FU duration: 15 days

Metoprolol (initial dose intravenously) (n=25)

vs.

(n=26)

Double

Sample size: 25/26

Primary endpoint:

FU duration: 14 days

Practolol, (initial dose intravenously) H87/07, or metoprolol (n=38)

vs.

(n=45)

Double

Sample size: 38/45

Primary endpoint:

FU duration: 1 week

Metoprolol (initial dose intravenously) (15 mg) (n=696)

vs.

(n=694)

No

Sample size: 696/694

Primary endpoint:

FU duration: 5 days

Metoprolol 100mg twice daily (initial dose intravenously) (n=698)

vs.

placebo (n=697)

Double blind

Parallel groups

Sample size: 698/697

Primary endpoint: all cause death

FU duration: 2 years

Metoprolol 100 mg bid (n=1195)

vs.

placebo (n=1200)

treatment continued for up to 1 year

Double blind

Parallel groups

Sample size: 1195/1200

Primary endpoint: all-cause mortality

FU duration: 18 months

Metoprolol 100mg twice daily (n=273)

vs.

placebo (n=280)

Double blind

Parallel groups

Sample size: 273/280

Primary endpoint: NA

FU duration: 1 year

Metoprolol 100mg twice daily (n=154)

vs.

placebo (n=147)

Double blind

Parallel groups

Sample size: 154/147

Primary endpoint: NA

FU duration: 36 months

Metoprolol 100 mg twice daily for one year (initial dose intravenously) (n=416)

vs.

placebo (n=384)

Double blind

Parallel groups

Sample size: 416/384

Primary endpoint: NA

FU duration: 1 year

all cause death 1.38 [0.47; 4.03]

all cause death 1.79 [0.82; 3.92]

all cause death 0.69 [0.29; 1.67]

all cause death 1.41 [0.65; 3.08]

all cause death 1.30 [0.89; 1.91]

cardiovascular death 1.31 [0.88; 1.96]

Sudden death 1.07 [0.62; 1.86]

cardiac death 1.67 [0.90; 3.10]

all cause death 0.48 [0.27; 0.83]

cardiovascular death 0.40 [0.22; 0.74]

fatal and nonfatal MI 0.47 [0.27; 0.79]

reinfarction 0.00 [0.00; NaN]

all cause death 0.93 [0.65; 1.34]

fatal and nonfatal MI 0.87 [0.69; 1.10]

reinfarction 0.86 [0.62; 1.20]

cardiac event (fatal and non fatal ) 0.87 [0.69; 1.10]

Oxprenolol (n=177)

vs.

(n=136)

Double

Sample size: 177/136

Primary endpoint:

FU duration: 8 weeks

Oxprenolol (n=106)

vs.

(n=114)

Unclear

Sample size: 106/114

Primary endpoint:

FU duration: 21 days

Oxprenolol (n=133)

vs.

(n=127)

Double

Sample size: 133/127

Primary endpoint:

FU duration: 20 days

Oxprenolol (n=157)

vs.

(n=158)

Double

Sample size: 157/158

Primary endpoint:

FU duration: 6 weeks

Oxprenolol slow release 160 mg b.i.d. (n=858)

vs.

placebo (n=883)

Double blind

Parallel groups

Sample size: 858/883

Primary endpoint: NA

FU duration: 1 year

Oxprenolol 160mg daily (n=485)

vs.

placebo (n=488)

Double blind

Parallel groups

Sample size: 485/488

Primary endpoint: sudden death

FU duration: 22 months (at least 6mo)

Oxprenolol 40mg twice daily (n=632)

vs.

placebo (n=471)

Double blind

Parallel groups

Sample size: 632/471

Primary endpoint: cardiac event

FU duration: 48 months

all cause death 1.00 [0.06; 15.55]

all cause death 0.97 [0.67; 1.40]

Sudden death 0.91 [0.56; 1.48]

cardiac death 0.94 [0.63; 1.40]

reinfarction 0.93 [0.43; 2.01]

Pindolol (initial dose intravenously) (n=50)

vs.

(n=50)

No

Sample size: 50/50

Primary endpoint:

FU duration: 3 days

Pindolol 15 mg daily (n=263)

vs.

placebo (n=266)

Double blind

Parallel groups

Sample size: 263/266

Primary endpoint: Death

FU duration: 2 years

all cause death 1.57 [0.60; 4.05]

all cause death 1.16 [0.47; 2.86]

all cause death ∞ [NaN; ∞]

all cause death 1.12 [0.62; 2.02]

all cause death 0.82 [0.26; 2.57]

Sudden death 0.57 [0.36; 0.91]

cardiac death 0.75 [0.57; 0.99]

all cause death 0.80 [0.62; 1.02]

reinfarction 0.77 [0.57; 1.04]

Practolol (initial dose intravenously) (n=46)

vs.

(n=48)

No

Sample size: 46/48

Primary endpoint:

FU duration: 7 months

Practolol (initial dose intravenously) then atenolol (n=25)

vs.

(n=29)

Single

Sample size: 25/29

Primary endpoint:

FU duration: 6 months

Practolol (initial dose intravenously) (n=26)

vs.

(n=26)

Unclear

Sample size: 26/26

Primary endpoint:

FU duration: 1 week

Practolol (n=76)

vs.

(n=67)

Unclear

Sample size: 76/67

Primary endpoint:

FU duration: Short term

Practolol (n=72)

vs.

(n=71)

Double

Sample size: 72/71

Primary endpoint:

FU duration: 1 year

Practolol 200mg twice daily (n=1533)

vs.

placebo (n=1520)

Double blind

Parallel groups

Sample size: 1533/1520

Primary endpoint: death, reinfarction

FU duration: 12 months, up to 24 months

all cause death 0.97 [0.52; 1.81]

all cause death 0.75 [0.36; 1.58]

all cause death 0.92 [0.53; 1.58]

all cause death NaN [NaN; NaN]

all cause death 0.80 [0.23; 2.74]

all cause death 0.00 [0.00; NaN]

all cause death NaN [NaN; NaN]

all cause death NaN [NaN; NaN]

all cause death 0.41 [0.11; 1.50]

all cause death 0.67 [0.12; 3.78]

all cause death 2.00 [0.19; 21.06]

all cause death 1.19 [0.59; 2.40]

all cause death NaN [NaN; NaN]

all cause death 1.30 [0.79; 2.15]

all cause death NaN [NaN; NaN]

all cause death 1.09 [0.53; 2.23]

all cause death 0.51 [0.05; 5.44]

all cause death NaN [NaN; NaN]

all cause death 1.21 [0.70; 2.08]

all cause death NaN [NaN; NaN]

all cause death 0.66 [0.17; 2.66]

all cause death 0.73 [0.58; 0.93]

cardiac death 0.71 [0.55; 0.93]

cardiac event (fatal and non fatal ) 0.72 [0.59; 0.89]

reinfarction 0.60 [0.15; 2.43]

all cause death 1.07 [0.64; 1.77]

fatal and nonfatal MI 1.03 [0.51; 2.07]

cardiac death 0.62 [0.33; 1.15]

reinfarction 1.03 [0.51; 2.07]

all cause death 0.74 [0.60; 0.91]

cardiovascular death 0.74 [0.60; 0.93]

cardiac death 0.73 [0.58; 0.91]

reinfarction 0.85 [0.66; 1.10]

Sudden death 0.49 [0.24; 0.98]

fatal and nonfatal MI 1.49 [1.03; 2.18]

all cause death 0.69 [0.42; 1.11]

cardiac death 0.69 [0.47; 1.00]

reinfarction 0.77 [0.41; 1.45]

cardiac event (fatal and non fatal ) 0.73 [0.49; 1.10]

all cause death 0.94 [0.56; 1.58]

cardiovascular death 0.86 [0.50; 1.47]

Propranolol (n=56)

vs.

(n=58)

Double

Sample size: 56/58

Primary endpoint:

FU duration: 28 days

Propranolol (n=52)

vs.

(n=47)

No

Sample size: 52/47

Primary endpoint:

FU duration: 4 weeks

Propranolol (n=66)

vs.

(n=64)

Unclear

Sample size: 66/64

Primary endpoint:

FU duration: 14 days

Propranolol 240mg/d (n=18)

vs.

placebo (n=12)

Double

Sample size: 18/12

Primary endpoint:

FU duration: 3.4 days

Propranolol (n=36)

vs.

(n=36)

No

Sample size: 36/36

Primary endpoint:

FU duration: 36 weeks

Propranolol (n=25)

vs.

(n=25)

Unclear

Sample size: 25/25

Primary endpoint:

FU duration: Unclear

Propranolol (initial dose intravenously) (n=15)

vs.

(n=15)

No

Sample size: 15/15

Primary endpoint:

FU duration: 72 hours

Propranolol (n=16)

vs.

(n=13)

Unclear

Sample size: 16/13

Primary endpoint:

FU duration: 2 days

Propranolol (n=38)

vs.

(n=31)

Double

Sample size: 38/31

Primary endpoint:

FU duration: Up to 35 days

Propranolol (n=40)

vs.

(n=40)

Double

Sample size: 40/40

Primary endpoint:

FU duration: 7 days

Propranolol (initial dose intravenously) (n=35)

vs.

(n=35)

Double

Sample size: 35/35

Primary endpoint:

FU duration: To discharge

Propranolol (n=100)

vs.

(n=95)

Double

Sample size: 100/95

Primary endpoint:

FU duration: 28 days

Propranolol (initial dose intravenously) (n=20)

vs.

(n=20)

Unclear

Sample size: 20/20

Primary endpoint:

FU duration: 1 week

Propranolol (n=226)

vs.

(n=228)

Double

Sample size: 226/228

Primary endpoint:

FU duration: 3 weeks

Propranolol (initial dose intravenously) (n=20)

vs.

(n=23)

No

Sample size: 20/23

Primary endpoint:

FU duration: To discharge

Propranolol (initial dose intravenously) (n=364)

vs.

(n=371)

No

Sample size: 364/371

Primary endpoint:

FU duration: In hospital

Propranolol (initial dose intravenously) (n=47)

vs.

(n=48)

No

Sample size: 47/48

Primary endpoint:

FU duration: To discharge

Propranolol (n=9)

vs.

(n=8)

Double

Sample size: 9/8

Primary endpoint:

FU duration: 14 days

Propranolol (initial dose intravenously) (n=134)

vs.

(n=135)

Single

Sample size: 134/135

Primary endpoint:

FU duration: 36 months

Propranolol (initial dose intravenously) (n=8)

vs.

(n=7)

No

Sample size: 8/7

Primary endpoint:

FU duration: 60 hours

Propranolol (initial dose intravenously) (n=26)

vs.

(n=23)

No

Sample size: 26/23

Primary endpoint:

FU duration: To discharge

Propranolol 30 mg 3 times daily (n=79)

vs.

no propranolol (n=79)

Parallel groups

Sample size: 79/79

Primary endpoint: NA

FU duration: 1 year

Propranolol 40 mg three times a day (n=355)

vs.

placebo (n=365)

Double blind

Parallel groups

Sample size: 355/365

Primary endpoint: NA

FU duration: 9 months

Propranolol 180 or 240 mg/day (n=1916)

vs.

placebo (n=1921)

Double blind

Parallel groups

Sample size: 1916/1921

Primary endpoint: all-cause mortality

FU duration: 25 months

Propranolol 40mg four times a day (n=278)

vs.

placebo (n=282)

Double blind

Parallel groups

Sample size: 278/282

Primary endpoint: NA (sudden cardiac death may be)

FU duration: 1 year

Propranolol 40 mg three times daily(initial dose intravenously) n=132 or atenolol 50 mg twice daily n=127 (n=259)

vs.

placebo (n=129)

Double blind

Parallel groups

Sample size: 259/129

Primary endpoint: NA

FU duration: 1 year

all cause death NaN [NaN; NaN]

Sotalol (initial dose intravenously) (n=15)

vs.

(n=15)

No

Sample size: 15/15

Primary endpoint:

FU duration: 72 hours

all cause death 0.48 [0.05; 4.82]

all cause death ∞ [NaN; ∞]

all cause death 0.73 [0.17; 3.14]

all cause death 0.36 [0.04; 3.36]

all cause death 1.10 [0.07; 16.96]

all cause death 0.79 [0.22; 2.77]

all cause death 0.64 [0.51; 0.81]

cardiovascular death 0.58 [0.45; 0.75]

Sudden death 0.49 [0.35; 0.69]

cardiac death 0.58 [0.45; 0.75]

reinfarction 0.62 [0.48; 0.80]

Timolol (initial dose intravenously) (n=20)

vs.

(n=19)

Unclear

Sample size: 20/19

Primary endpoint:

FU duration: In hospital

Timolol (initial dose intravenously) (n=50)

vs.

(n=50)

Unclear

Sample size: 50/50

Primary endpoint:

FU duration: 28 days

Timolol (initial dose intravenously) (n=73)

vs.

(n=71)

Double

Sample size: 73/71

Primary endpoint:

FU duration: To discharge

Timolol (initial dose intravenously) (n=45)

vs.

(n=49)

Double IV open orally

Sample size: 45/49

Primary endpoint:

FU duration: 28 days

Timolol (n=42)

vs.

(n=46)

Double

Sample size: 42/46

Primary endpoint:

FU duration: 1 year

Timolol (n=56)

vs.

(n=55)

Double

Sample size: 56/55

Primary endpoint:

FU duration: To discharge

Timolol 10mg twice daily (n=945)

vs.

placebo (n=939)

Double blind

Parallel groups

Sample size: 945/939

Primary endpoint: NA

FU duration: 17 months

all cause death NaN [NaN; NaN]

Xamoterol (n=25)

vs.

(n=26)

Double

Sample size: 25/26

Primary endpoint:

FU duration: 7 days

all cause death 0.49 [0.09; 2.50]

confirmed myocardial infarction 0.97 [0.84; 1.13]

Diltiazem 360mg IV/24h plus 360mh/24h orally (n=38)

vs.

(n=37)

single blind

Parallel groups

Sample size: 38/37

Primary endpoint: infract size

FU duration: 21 days

all cause death 1.23 [0.52; 2.93]

all cause death 1.00 [0.82; 1.22]

cardiac death 1.03 [0.81; 1.30]

reinfarction 0.85 [0.66; 1.10]

confirmed myocardial infarction 1.06 [0.94; 1.20]

Diltiazem 90mgx4 (n=287)

vs.

placebo (n=289)

double blind

Parallel groups

Sample size: 287/289

Primary endpoint: reinfarction

FU duration: 14 days

Diltiazem 60mgx4 (n=1234)

vs.

placebo (n=1232)

Double blind

Parallel groups

Sample size: 1234/1232

Primary endpoint: NA

FU duration: 25 months (at least 12 months)

Diltiazem 10-20mg/h IV, 4x60mg orraly (n=17)

vs.

placebo (n=17)

double blind

Parallel groups

Sample size: 17/17

Primary endpoint: infract size

FU duration:

all cause death 3.31 [0.71; 15.51]

confirmed myocardial infarction 0.99 [0.86; 1.13]

all cause death NaN [NaN; NaN]

confirmed myocardial infarction 1.00 [1.00; 1.00]

Nifedipine 20mgx6 (n=93)

vs.

(n=88)

double blind

Parallel groups

Sample size: 93/88

Primary endpoint: infarct development

FU duration: 14 days

Nifedipine 10 mgx4 (n=13)

vs.

(n=13)

single blind

Parallel groups

Sample size: 13/13

Primary endpoint: haemodynamics

FU duration: 1 day

Nifedipine 3-4x60mg (n=904)

vs.

(n=888)

open

Parallel groups

Sample size: 904/888

Primary endpoint: mortality

FU duration:

all cause death NaN [NaN; NaN]

confirmed myocardial infarction 1.22 [NaN; NaN]

all cause death 1.59 [0.53; 4.74]

confirmed myocardial infarction 1.24 [0.81; 1.89]

all cause death ∞ [NaN; ∞]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 1.06 [0.28; 4.07]

confirmed myocardial infarction 1.12 [0.97; 1.29]

all cause death 1.69 [0.65; 4.41]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 1.01 [0.73; 1.42]

cardiac death 1.01 [0.70; 1.47]

reinfarction 0.92 [0.63; 1.34]

all cause death 1.16 [0.90; 1.51]

confirmed myocardial infarction 0.96 [0.92; 1.01]

confirmed myocardial infarction 1.00 [1.00; 1.00]

confirmed myocardial infarction 1.00 [0.95; 1.04]

confirmed myocardial infarction 0.98 [0.86; 1.11]

confirmed myocardial infarction 0.92 [0.77; 1.09]

Nifedipine 20mgx4 (n=25)

vs.

placebo (n=25)

double blind

Parallel groups

Sample size: 25/25

Primary endpoint: chest pain

FU duration: 12 days

Nifedipine 10mgx4 (n=60)

vs.

placebo (n=61)

double blind

Parallel groups

Sample size: 60/61

Primary endpoint: infract size

FU duration: 2 days

Nifedipine 6x20mg (n=13)

vs.

placebo (n=9)

single blind

Parallel groups

Sample size: 13/9

Primary endpoint:

FU duration: 7 days

Nifedipine 10 to 30mgx4 (n=64)

vs.

placebo (n=68)

double blind

Parallel groups

Sample size: 64/68

Primary endpoint: LV function

FU duration: 42 days

Nifedipine 20mgx3 (n=74)

vs.

placebo (n=75)

double blind

Parallel groups

Sample size: 74/75

Primary endpoint: infract size

FU duration: hospital stay

Nifedipine 10mgx3 (n=1130)

vs.

placebo (n=1146)

Double blind

Parallel groups

Sample size: 1130/1146

Primary endpoint: mortality

FU duration: 1 year

Nifedipine 20mgx3 started within 3hr of hopsital admission for 6 months (n=682)

vs.

placebo (n=676)

Double blind

Parallel groups

Sample size: 682/676

Primary endpoint: two primary endpoints: non fatal MI and mortality

FU duration: 6 months

Nifedipine 4x10mg (n=23)

vs.

placebo (n=34)

double blind

Parallel groups

Sample size: 23/34

Primary endpoint: infract size

FU duration:

Nifedipine 4x10mg (n=2240)

vs.

placebo (n=2251)

double blind

Parallel groups

Sample size: 2240/2251

Primary endpoint: mortality

FU duration: 28 days

Nifedipine 6x10mg for 48hrs (n=217)

vs.

placebo (n=217)

double blind

Parallel groups

Sample size: 217/217

Primary endpoint: infract size

FU duration:

Nifedipine 5x10mg (n=112)

vs.

placebo (n=115)

double blind

Parallel groups

Sample size: 112/115

Primary endpoint: infract size

FU duration: 42 days

all cause death NaN [NaN; NaN]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 0.00 [0.00; NaN]

confirmed myocardial infarction 1.00 [1.00; 1.00]

all cause death 0.82 [0.63; 1.05]

cardiac death 0.80 [0.61; 1.05]

all cause death 1.06 [0.64; 1.73]

cardiac death 0.97 [0.54; 1.75]

reinfarction 0.81 [0.54; 1.22]

confirmed myocardial infarction 0.99 [0.92; 1.07]

Verapamil 5 to 10 mg/h IV (n=29)

vs.

no treatment (n=25)

open

Parallel groups

Sample size: 29/25

Primary endpoint: infract size

FU duration: 2 days

verapamil 120mgx3 (n=1751)

vs.

placebo (n=1747)

Double blind

Parallel groups

Sample size: 1751/1747

Primary endpoint: all-cause mortality

FU duration: 6 months

verapamil 80mgx3 (n=8)

vs.

placebo (n=9)

single blind

Parallel groups

Sample size: 8/9

Primary endpoint: angina and reinfarction

FU duration: 10 days

verapamil 120mgx3 for 18 months (n=878)

vs.

placebo (n=897)

Double blind

Parallel groups

Sample size: 878/897

Primary endpoint: all-cause mortality and firstmajor event

FU duration: 16 months

verapamil retard 360 mg daily (n=531)

vs.

placebo (n=542)

Double blind

Parallel groups

Sample size: 531/542

Primary endpoint: all-cause mortality

FU duration: 23.5 months

verapamil 0.1mg/kg IV plus 3x120mg orally (n=1729)

vs.

placebo (n=1718)

double blind

Parallel groups

Sample size: 1729/1718

Primary endpoint: mortality

FU duration: 12 months

MACE 0.48 [0.22; 1.04]

Cardiovascular death 0.51 [0.05; 5.54]

Emergency PCI for in-stent thrombosis/reinfarction/unstable angina 0.56 [0.19; 1.65]

Stroke 1.01 [0.06; 16.09]

Heart failure 0.14 [0.02; 1.17]

single bolus of 60,000 IU epoetin alfa administered intravenously within three hours after a successful PCI (n=263)

vs.

control (n=266)

open

Parallel groups

Sample size: 263/266

Primary endpoint: left ventricular ejection fraction

FU duration: 6 weeks

Death 0.76 [0.05; 11.39]

CHF NaN [NaN; NaN]

Death or MI 1.52 [0.15; 15.55]

MI ∞ [NaN; ∞]

CHF 0.09 [0.01; 0.66]

Death 0.22 [0.03; 1.90]

Death or MI 0.35 [0.12; 1.04]

MI 0.38 [0.11; 1.37]

Death 2.13 [0.20; 22.31]

CHF 0.71 [0.22; 2.28]

Death or MI 5.31 [0.66; 43.04]

MI 3.19 [0.35; 29.09]

Death 0.84 [0.34; 2.09]

CHF 0.57 [0.14; 2.31]

Death or MI 0.94 [0.43; 2.08]

MI 1.26 [0.29; 5.49]

Death 0.00 [0.00; NaN]

CHF 0.00 [0.00; NaN]

Death or MI 0.00 [0.00; NaN]

MI NaN [NaN; NaN]

Death 1.04 [0.78; 1.38]

CHF 0.98 [0.65; 1.48]

Death or MI 1.20 [0.95; 1.51]

MI 1.34 [0.92; 1.97]

late PTCA (n=25)

vs.

no PTCA (n=19)

open

Sample size: 25/19

Primary endpoint: Left ventricular ejection fraction

FU duration: 4 months, fixed

late revascularization by primary PTCA (n=44)

vs.

no PTCA (n=39)

Sample size: 44/39

Primary endpoint:

FU duration: 50 months, mean

late revascularization (late intervention and stent to the LAD + medical therapy) (n=32)

vs.

conservative therapy (medical therapy) (n=34)

open

Sample size: 32/34

Primary endpoint:

FU duration: 12 months, fixed

percutaneous revascularization carried out 2-15 days after symptom onset (n=109)

vs.

medical treatment (n=103)

open

Sample size: 109/103

Primary endpoint:

FU duration: 34 months, mean

percutaneous coronary intervention (n=18)

vs.

conservative therapy (no-PCI) (n=18)

open

Sample size: 18/18

Primary endpoint:

FU duration: 6 months, fixed

routine PCI and stenting (n=1082)

vs.

optimal medical therapy alone (n=1084)

open

Sample size: 1082/1084

Primary endpoint:

FU duration: 35 months, mean

PCI with stenting (n=195)

vs.

optimal medical therapy alone (n=186)

open

Sample size: 195/186

Primary endpoint: IRA patency and change in LV ejection fraction

FU duration: 12 months, fixed

Short-term death 0.84 [0.25; 2.90]

Short-term major bleeding 2.11 [0.41; 10.83]

Final TIMI 3 flow 1.16 [0.94; 1.44]

Initial TIMI 3 flow 1.41 [0.34; 5.86]

Short-term death 0.00 [0.00; NaN]

Short-term major bleeding 0.92 [0.06; 14.35]

Short-term non-fatal reinfarction ∞ [NaN; ∞]

Short-term urgent target vessel revascularisation 1.23 [0.29; 5.22]

Final TIMI 3 flow 1.09 [0.92; 1.29]

Initial TIMI 3 flow 1.08 [0.73; 1.61]

Initial TIMI 3 flow 9.00 [1.18; 68.70]

Short-term death 0.00 [0.00; NaN]

Short-term major bleeding 1.45 [0.74; 2.85]

Short-term non-fatal reinfarction NaN [NaN; NaN]

Short-term urgent target vessel revascularisation 0.00 [0.00; NaN]

Final TIMI 3 flow 0.98 [0.87; 1.11]

Final TIMI 3 flow 2.10 [1.47; 3.00]

Short-term death NaN [NaN; NaN]

Short-term major bleeding 0.48 [0.05; 5.01]

Short-term non-fatal reinfarction NaN [NaN; NaN]

Short-term urgent target vessel revascularisation 0.00 [0.00; NaN]

Initial TIMI 3 flow 3.86 [0.90; 16.55]

Initial TIMI 3 flow 3.46 [1.07; 11.22]

Short-term death 1.04 [0.07; 15.76]

Short-term major bleeding 0.52 [0.05; 5.39]

Short-term non-fatal reinfarction NaN [NaN; NaN]

Short-term urgent target vessel revascularisation NaN [NaN; NaN]

Final TIMI 3 flow 1.12 [0.95; 1.33]

Short-term major bleeding in patients treated 1.81 [1.07; 3.05]

Short-term death 1.16 [0.75; 1.79]

Short-term non-fatal reinfarction 1.10 [0.55; 2.19]

facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion (n=36)

vs.

primary intervention (n=38)

Sample size: 36/38

Primary endpoint:

FU duration: 30-day

facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion (n=52)

vs.

primary intervention (n=48)

Sample size: 52/48

Primary endpoint:

FU duration: 30-day

facilated PCI with Abciximab; 0·25 mg/kg intravenous bolus, 0·125 µg/kg per min infusion (n=56)

vs.

primary intervention (n=56)

Sample size: 56/56